drugset / Trial / NCT02960646
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.
Timeline
- Start
- 2017-01-18
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Melphalan | Small molecule | — | Intravenous |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | Tacrolimus | Small molecule | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |